This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

. 2020 Feb;29(2):115-116.

doi: 10.1080/13543784.2020.1721167. Epub 2020 Feb 3.

Nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): prevalence, therapeutic innovations, and stumbling blocks for clinical development

Naim Alkhouri¹

Affiliations

PMID: 31971024
DOI: 10.1080/13543784.2020.1721167

Nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): prevalence, therapeutic innovations, and stumbling blocks for clinical development

Naim Alkhouri. Expert Opin Investig Drugs. 2020 Feb.

. 2020 Feb;29(2):115-116.

doi: 10.1080/13543784.2020.1721167. Epub 2020 Feb 3.

Author

Naim Alkhouri¹

Affiliation

¹ Texas Liver Institute, University of Texas (UT) Health San Antonio, San Antonio, TX, USA.

PMID: 31971024
DOI: 10.1080/13543784.2020.1721167

No abstract available

Keywords: NAFLD; nash; nonalcoholic fatty liver disease; nonalcoholic steatohepatitis; obeticholic acid; regenerate trial; type-2 diabetes.

PubMed Disclaimer

Similar articles

Effectiveness of lifestyle interventions in NAFLD (nonalcoholic fatty liver disease) - how are clinical trials affected?
Michel M, Schattenberg JM. Michel M, et al. Expert Opin Investig Drugs. 2020 Feb;29(2):93-97. doi: 10.1080/13543784.2020.1716333. Epub 2020 Jan 21. Expert Opin Investig Drugs. 2020. PMID: 31933385 No abstract available.
[Overview of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis Management].
Kim SK, Kim KI, Kim SR. Kim SK, et al. Yakugaku Zasshi. 2019;139(9):1147-1153. doi: 10.1248/yakushi.19-00011-1. Yakugaku Zasshi. 2019. PMID: 31474630 Review. Japanese.
NASH and NAFLD: emerging drugs, therapeutic targets and translational and clinical challenges.
Alkhouri N. Alkhouri N. Expert Opin Investig Drugs. 2020 Feb;29(2):87. doi: 10.1080/13543784.2020.1721169. Epub 2020 Jan 29. Expert Opin Investig Drugs. 2020. PMID: 31984804 No abstract available.
Nonalcoholic Fatty Liver Disease.
Sweet PH, Khoo T, Nguyen S. Sweet PH, et al. Prim Care. 2017 Dec;44(4):599-607. doi: 10.1016/j.pop.2017.07.003. Prim Care. 2017. PMID: 29132522 Review.
Multi-drug approaches to NASH: what's in the development pipeline?
Johnston MP, Patel J, Byrne CD. Johnston MP, et al. Expert Opin Investig Drugs. 2020 Feb;29(2):143-150. doi: 10.1080/13543784.2020.1668926. Epub 2019 Sep 23. Expert Opin Investig Drugs. 2020. PMID: 31524533 Review.

See all similar articles

Cited by

Inhibition of Extracellular Cathepsin D Reduces Hepatic Lipid Accumulation and Leads to Mild Changes in Inflammationin NASH Mice.
Yadati T, Houben T, Bitorina A, Oligschlaeger Y, Gijbels MJ, Mohren R, Lütjohann D, Khurana P, Goyal S, Kulkarni A, Theys J, Cillero-Pastor B, Shiri-Sverdlov R. Yadati T, et al. Front Immunol. 2021 Jul 16;12:675535. doi: 10.3389/fimmu.2021.675535. eCollection 2021. Front Immunol. 2021. PMID: 34335574 Free PMC article.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Atypon
Medical
- MedlinePlus Health Information